Shree Anand Life Sciences
Shree Anand Life Sciences Ltd is a Belagavi-based, privately held pharmaceutical manufacturer of sterile Small Volume Parenteral (SVP) injectable formulations — liquid, dry powder, lyophilized, and pre-filled syringe products — sold on a B2B basis to domestic and export pharmaceutical buyers.
- Company typePrivate
- Founded-
- HeadquartersBelgami, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Shree Anand Life Sciences does
Shree Anand Life Sciences Ltd (SALSL) is a privately held, Belagavi (Karnataka, India)-based pharmaceutical manufacturer specializing in sterile Small Volume Parenteral (SVP) injectable formulations. The company was established by the promoters of Anand Pharmaceuticals, a formulation unit operating in North Karnataka since 1989, and commissioned its modern cGMP-compliant manufacturing facility at Plot No 63 A & B, Honaga Industrial Area in or around 2021. SALSL produces liquid injections (in ampoules, vials, and pre-filled syringes), dry powdered injections, and lyophilized injections across therapeutic categories including anticoagulants (Enoxaparin), proton pump inhibitors (Rabeprazole Sodium), neuromuscular blockers (Atracurium Besylate, Cisatracurium), NSAIDs (Diclofenac), corticosteroids (Dexamethasone, Hydrocortisone), antimalarials (Artesunate 60mg/120mg), and antifungals (Amphotericin-B). The Belagavi site holds WHO GMP, GMP, GLP, and ISO 9001:2015 accreditations and is operated under the leadership of Satish M Gharge (Chairman & Managing Director), who has been in pharmaceutical manufacturing since 1987.
The company's underlying technology platform is a single-site aseptic manufacturing stack rather than a software platform. The 2-acre Belagavi plant is configured with Class C processing areas and Class A/B filtration and filling zones, ISO-5 to ISO-8 cleanrooms served by 27 air handling units, 13 exhaust systems, and 10 ventilation units with terminal HEPA filtration at 99.997% efficiency. Utilities are produced in-house: a Multi Effect Distillation Still produces Water for Injection (WFI) stored in SS 316L tanks at above 80°C, and on-site nitrogen is generated at 99.99% purity at 10 m³/hour. Production equipment includes CIP/SIP vessels, washing machines, sterilizing tunnels, lyophilizers, pre-filled syringe filling machines, and an automatic 100% visual inspection machine; QC is GLP- and 21 CFR-compliant with UV/VIS, FTIR, TOC, HPLC, GC, and analytical balances.
SALSL's business model is B2B contract-manufacturing of sterile injectables, selling to domestic Indian pharmaceutical buyers and export-market clients, with pricing conducted on a quote basis (no public pricing, no disclosed license economics). The company is privately held, has no external funding rounds or institutional investors on record, and operates with a headcount in the 51–100 range. Distribution is direct to enterprise pharma buyers; social channels (LinkedIn, Facebook, YouTube) are used only for top-of-funnel visibility.
Shree Anand Life Sciences firmographics
Firmographics- Name
- Shree Anand Life Sciences
- Legal name
- Shree Anand Life Sciences Ltd
- Website
- https://salsl.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Shree Anand Life Sciences Ltd is a Belagavi-based, privately held pharmaceutical manufacturer of sterile Small Volume Parenteral (SVP) injectable formulations — liquid, dry powder, lyophilized, and pre-filled syringe products — sold on a B2B basis to domestic and export pharmaceutical buyers.
- Ownership category
- akta.pro rank
Shree Anand Life Sciences industry classification
Industry- Product category
- Sterile Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Generic Hospital & Institutional ProductsSpecialty Injectable & Infusion Therapies (Cross-therapeutic)
Keywords
Where Shree Anand Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Belgami
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Shree Anand Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Injectable Formulations: B2B sale of sterile injectable pharmaceutical products including liquid injections (ampoules, vials, pre-filled syringes), dry powdered injections, and lyophilized injections to domestic and export markets.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Shree Anand Life Sciences product offering
Product offeringCore offering
Shree Anand Life Sciences Limited manufactures and sells Small Volume Parenteral (SVP) sterile injectable pharmaceutical formulations under cGMP conditions. Its product range spans liquid injections in ampoules, vials, and pre-filled syringes, dry powdered injections, and lyophilized injections, covering therapeutic categories including anticoagulants, proton pump inhibitors, neuromuscular blocking agents, NSAIDs, corticosteroids, antimalarials, and antifungals for B2B customers in domestic and export markets.
Product overview
Shree Anand Life Sciences Ltd operates as a pharmaceutical manufacturer specializing in Small Volume Parenteral (SVP) injectable formulations. The company produces a portfolio of sterile injectable products across four main categories: Liquid Injections (manufactured in ampoules, vials, and pre-filled syringes), Dry Powdered Injections, and Lyophilized Injections. The product portfolio includes therapeutic categories such as anticoagulants (Enoxaparin), proton pump inhibitors (Rabeprazole Sodium), neuromuscular blocking agents (Atracurium Besylate, Cisatracurium), NSAIDs (Diclofenac), corticosteroids (Dexamethasone, Hydrocortisone), antimalarials (Artesunate), and antifungals (Amphotericin-B). The company manufactures all products under cGMP conditions with capabilities including CIP/SIP vessels, washing machines, sterilizing tunnels, filling machines, lyophilizers, and pre-filled filling machines, with processing conducted in Class C environments and filtration/filling in Class A/B areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Liquid Injections Sterile liquid injectable formulations manufactured in ampoules, vials, and pre-filled syringes for therapeutic delivery to pharmaceutical companies and healthcare providers in domestic and export markets.
- Dry Powdered Injections Sterile injectable formulations in dry powder form requiring reconstitution prior to administration, supplied to pharmaceutical companies and healthcare providers.
- Lyophilized Injections Freeze-dried sterile injectable products designed for enhanced stability and extended shelf life, supplied to pharmaceutical companies and healthcare providers.
- Enoxaparin Injection 60mg Anticoagulant (blood thinner) delivered in sterile pre-filled syringes, used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), including during pregnancy and following certain types of surgery.
- Rabeprazole Sodium 20mg Proton pump inhibitor injectable formulation for reducing stomach acid production, supplied to pharmaceutical companies and healthcare providers.
- Atracurium Besylate Injection Neuromuscular blocking agent injectable formulation used as an anesthesia adjunct for surgical procedures, supplied to pharmaceutical companies and healthcare providers.
- Diclofenac 75mg Non-steroidal anti-inflammatory drug (NSAID) injectable formulation for pain and inflammation management, supplied to pharmaceutical companies and healthcare providers.
- Cisatracurium Neuromuscular blocking agent injectable formulation, supplied to pharmaceutical companies and healthcare providers for surgical and critical care use.
- Dexamethasone Corticosteroid injectable formulation for anti-inflammatory and immunosuppressive applications, supplied to pharmaceutical companies and healthcare providers.
- Hydrocortisone Corticosteroid injectable formulation for anti-inflammatory applications, supplied to pharmaceutical companies and healthcare providers.
- Artesunate 120mg Antimalarial injectable formulation at 120mg strength for treating severe malaria, supplied to pharmaceutical companies and healthcare providers.
- Artesunate 60mg Antimalarial injectable formulation at 60mg strength for treating severe malaria, supplied to pharmaceutical companies and healthcare providers.
- Amphotericin-B Antifungal injectable formulation for treating serious systemic fungal infections, supplied to pharmaceutical companies and healthcare providers.
Companies that use Shree Anand Life Sciences
Customer profileSegments2 records
Ideal customer profiles1 record
Shree Anand Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Shree Anand Life Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Anand PharmaceuticalscorePromoters of SALSL are partners in Anand Pharmaceuticals, a formulation unit based in North Karnataka established in 1989. Anand Pharmaceuticals successfully set up a Small Volume Parenteral (SVP) injectable formulations plant at Mudhol, Karnataka, providing the foundation and expertise for SALSL's operations.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Shree Anand Life Sciences competitors and assessment
Company assessmentDirect peers
- Themis Medicare: Themis Medicare is an Indian pharmaceutical company with a focused sterile injectable portfolio covering anesthetics, analgesics, and critical care injectables. Its product overlap (Atracurium, Diclofenac family) and small-volume parenteral format make it a closely comparable mid-sized Indian injectable manufacturer.
- Gland Pharma: Gland Pharma is one of India's largest sterile injectable manufacturers with a portfolio spanning liquid injectables, lyophilized products, and pre-filled syringes, exporting globally including to the US. It is directly comparable to SALSL in SVP format mix and export-led growth, but at substantially larger scale (acquired by Fosun in 2022).
- Neon Laboratories: Neon Laboratories is an Indian manufacturer focused on sterile injectables including neuromuscular blockers, anesthetics, and critical care injectables. Its product overlap with SALSL molecules (Atracurium, Diclofenac, Dexamethasone) and small-volume parenteral focus make it a directly comparable Indian injectable specialist.
- Bharat Serums and Vaccines: Bharat Serums and Vaccines (BSV) is an India-based specialty injectables and biologics manufacturer producing lyophilized products, antisera, and hormonal injectables for hospital and critical care use. Its lyophilization capability and therapeutic-area focus overlap directly with SALSL's portfolio.
- Claris Lifesciences (now Aculife Healthcare): Claris Lifesciences (now Aculife Healthcare) is an Indian sterile injectable manufacturer producing liquid injectables, pre-filled syringes, and lyophilized products for hospital and institutional channels. It is the closest direct comparable to SALSL in product format, regulatory positioning (WHO GMP), and B2B GTM to pharmaceutical companies.
Broad incumbents
- Aurobindo Pharma: Aurobindo Pharma is a large Indian generic manufacturer with a growing sterile injectables business alongside oral solids and APIs. Its injectables franchise competes with SALSL on cost-sensitive molecules and institutional tenders, but within a much broader diversified pharma portfolio.
- Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company with a significant sterile injectables portfolio across multiple therapeutic areas including oncology, critical care, and anti-infectives. It is a broader incumbent in the same generic injectable space where SALSL competes, but at vastly greater scale, multi-site footprint, and global commercial reach.
- Dr. Reddy's Laboratories: Dr. Reddy's is a large Indian generic pharmaceutical company with a sterile injectables portfolio in oncology, anti-infectives, and pain management, exporting to regulated markets. It operates as a broad incumbent overlapping with SALSL on molecules such as Enoxaparin and other hospital injectables, but at enterprise scale with biologics, APIs, and biosimilars.
- Cipla: Cipla is a major Indian generic pharmaceutical company with a hospital injectables portfolio across anti-infectives, critical care, and respiratory. It competes with SALSL in the same domestic institutional injectable channels and exports globally, but as part of a much broader branded and generics franchise.
Regional players
- Alpa Laboratories: Alpa Laboratories is a smaller Indian manufacturer producing sterile injectables including small-volume parenterals, lyophilized products, and dry powder injections for domestic and export markets. Its scale and SVP product focus make it a closely comparable India-based peer with similar export orientation.
Market position
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Shree Anand Life Sciences social profiles
Digital presenceShree Anand Life Sciences compliance and trust
Trust signalCompliance5 records
Shree Anand Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shree Anand Life Sciences leadership team
Management profileNumber of profiles
Profiles1 record
Shree Anand Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shree Anand Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shree Anand Life Sciences
What does Shree Anand Life Sciences do?
Shree Anand Life Sciences Limited manufactures and sells Small Volume Parenteral (SVP) sterile injectable pharmaceutical formulations under cGMP conditions. Its product range spans liquid injections in ampoules, vials, and pre-filled syringes, dry powdered injections, and lyophilized injections, covering therapeutic categories including anticoagulants, proton pump inhibitors, neuromuscular blocking agents, NSAIDs, corticosteroids, antimalarials, and antifungals for B2B customers in domestic and export markets.
Is Shree Anand Life Sciences a public or private company?
Shree Anand Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Shree Anand Life Sciences founded?
Shree Anand Life Sciences was founded in -1. It employs 51 to 100 people.
Where is Shree Anand Life Sciences based?
Shree Anand Life Sciences is headquartered in Belgami, India, in the Asia region.
How does Shree Anand Life Sciences make money?
One revenue line is on record: pharmaceutical Injectable Formulations.
Who are Shree Anand Life Sciences's main competitors?
Direct peers on record are Themis Medicare, Gland Pharma, Neon Laboratories, Bharat Serums and Vaccines and Claris Lifesciences (now Aculife Healthcare). Broad incumbents are Aurobindo Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Cipla. Alpa Laboratories is listed as a regional player.
Does Shree Anand Life Sciences have an API?
No public API is recorded for Shree Anand Life Sciences.
What industry is Shree Anand Life Sciences in?
Shree Anand Life Sciences's product category is Sterile Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.